Every material Form 8-K Balchem filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Balchem reported results for the quarter ended September 30, 2026, with net sales of $290.7 million, up 8.6% from the prior year quarter, and GAAP net earnings of $46.7 million, up 16.0%. Diluted GAAP earnings per share were $1.46 versus $1.24, and all three reporting segments grew sales and earnings from operations, which points to improving results for shareholders.
Net sales were $290.7 million, up 8.6%; GAAP net earnings were $46.7 million, up 16.0%.
GAAP diluted EPS was $1.46 versus $1.24; adjusted EPS was $1.57 versus $1.35.
Free cash flow was $57.9 million; the company repurchased about $28 million of common stock in the quarter.
Net debt was $57.7 million with a leverage ratio of 0.2 times on a net debt basis.
Balchem reported second quarter 2026 results for the period ended June 30, with net sales of $284.0 million and GAAP net earnings of $44.6 million, both up from the prior year quarter. The filing also discloses a July 24, 2026 amendment that raised its senior secured revolving credit facility from $550 million to $650 million and extended its maturity to July 24, 2031.
Net sales were $284.0 million, up 11.2% from $255.5 million in the second quarter of 2025.
GAAP net earnings were $44.6 million, up 16.6%, and GAAP diluted EPS was $1.39 versus $1.17.
Adjusted EBITDA was $77.9 million, up 12.6%, and sales and earnings from operations rose in all three segments.
On July 24, 2026, the revolving credit facility was increased to $650 million and now matures July 24, 2031.
Balchem and its subsidiaries amended their credit agreement with JPMorgan Chase Bank, N.A. and JPMorgan SE. The revolving commitment rises from $550 million to $650 million, and the maturity moves from July 27, 2027 to July 24, 2031. The amendment also lowers borrowing margins at higher leverage levels and lets the foreign subsidiary Balchem B.V. borrow under the facility.
Aggregate revolving commitment increased from $550 million to $650 million
Maturity extended from July 27, 2027 to July 24, 2031
Margin reduced by 12.5 basis points in pricing tiers 3 and 4; pricing grid now runs from 1.00% to 1.500% for term benchmark loans based on net leverage
Balchem B.V. enabled to borrow; 10 basis point SOFR adjustment eliminated
Balchem Corporation reported first quarter 2026 results for the period ended March 31, 2026, with net sales up 8.1% and GAAP net earnings up 8.7% from the prior year quarter. Sales and earnings from operations grew in all three reporting segments, and the company reported strong cash flow, though the filing gives no full-year guidance.
Net sales were $270.7 million, up from $250.5 million in the first quarter of 2025.
GAAP net earnings were $40.3 million, and diluted EPS was $1.25 versus $1.13 a year earlier.
Adjusted EPS was $1.33 versus $1.22; free cash flow was $33.8 million.
Results were released April 30, 2026, with a conference call the same day at 11:00 AM ET.
Balchem reported fourth-quarter 2025 net sales of $263.6 million, up 9.8%, and GAAP diluted EPS of $1.21 versus $1.03 a year earlier. For full-year 2025, net sales were $1.037 billion, up 8.8%, and GAAP EPS was $4.75 versus $3.93, and the company said it increased its dividend by a double-digit percentage.
Q4 2025 net earnings were $39.2 million, up 16.8%, and adjusted EBITDA was $67.9 million, up 8.1%.
Q4 adjusted EPS was $1.31 versus $1.13 a year earlier.
Full-year 2025 net earnings were $154.8 million, up 20.5%, and free cash flow was $173.6 million.
Q4 share repurchases totaled $53.6 million, and net debt was $89.4 million at December 31, 2025.
Balchem Corporation said its Vice President and Chief Accounting Officer, William A. Backus, is retiring on March 31, 2026. The Board elected Erin L. Gilson, currently Senior Director, Accounting and Financial Reporting, to succeed him effective April 1, 2026. The filing says there are no material changes to Ms. Gilson's compensatory arrangement, so the change is an internal succession and does not alter the company's financial figures.
William A. Backus, Vice President and Chief Accounting Officer, retires March 31, 2026, as previously announced on March 3, 2025
Board elected Erin L. Gilson on February 12, 2026, as Vice President and Chief Accounting Officer, effective April 1, 2026
Ms. Gilson joined Balchem in February 2016 and currently serves as Senior Director, Accounting and Financial Reporting
No material changes to Ms. Gilson's compensatory arrangement as a result of this election
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Balchem filing is on SEC EDGAR ↗. 8-K briefs of other companies →